This site is intended for Healthcare professionals only.

Major depressive disorder linked to reduced arginine levels


Major depressive disorder linked to reduced arginine levels

Arginine is an amino acid which the body uses to produce, e.g., nitric oxide and whose bioavailability is known to be an independent risk factor of cardiovascular diseases.Now researchers from University of Eastern Finland in a study have found out that people suffering from major depressive disorder, MDD, have reduced arginine bioavailability and reduced arginine levels. The study has been published in Journal of Affective Disorders. 

“It is possible that depression-induced inflammatory responses lead to reduced arginine levels. This may result in insufficient production of nitric oxide for the needs of the nervous system and circulation. However, we don’t know yet what exactly causes reduced arginine bioavailability in people with depression,” says Doctoral Student Toni Ali-Sisto, the lead author of the study.

The study carried out by the University of Eastern Finland and Kuopio University Hospital involved 99 adults with diagnosed major depressive disorder and 253 non-depressed controls. The concentrations of three amino acids, namely arginine, citrulline and ornithine, were analysed from their fasting glucose samples, and this data was used to calculate their GABRs. Symmetric and asymmetric dimethylarginine concentrations were also measured, as they both play a role in the production of nitric oxide. The findings were then compared between the depressed and the non-depressed controls. The study also analysed whether these concentrations changed in people with depression during a follow-up of eight months, and whether remission of depression had an effect on the concentrations.

“Although our study shows that people with depression have reduced arginine bioavailability, this doesn’t mean that taking an arginine supplement would protect against depression. That’s an area for further research,” Ali-Sisto says.

People with depression had weaker arginine bioavailability than their non-depressed controls. The study did not find significant differences in the symmetric and asymmetric dimethylarginine concentrations. The use of anti-depressants or anti-psychotics did not affect the concentrations, either.

Contrary to the researchers’ expectations, there were no clear differences in the concentrations measured from people who had recovered from depression and people who remained depressed.

“Arginine bioavailability was slightly higher in people who had recovered from depression than in people who remained depressed. However, a more extensive set of data and a longer follow-up period are necessary for estimating arginine’s role in depression recovery.”

For more details click on the link: Journal of Affective Disorders, 2018; 229: 145 DOI: 10.1016/j.jad.2017.12.030

The following two tabs change content below.
Anjali Nimesh

Anjali Nimesh

Anjali Nimesh Joined Medical Dialogue as Reporter in 2016. she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Dr. Bhimrao Ambedkar University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Source: Press Release

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted